Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naïve Follicular Lymphoma
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, open label study to assess umbralisib in combination with ublituximab in
subjects with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).